Full Papers
An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients
L. Martínez-Estupiñán1, D. Hernández-Flórez2, I. Janta3, J.G. Ovalles-Bonilla4, J.C. Nieto5, C.M. González-Fernández6, T. Del Río7, I. Monteagudo8, F.J. López-Longo9, E. Naredo10, L. Valor11
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. lvalor.hgugm@salud.madrid.org
CER10156
2018 Vol.36, N°1
PI 0088, PF 0093
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 28850020 [PubMed]
Received: 07/12/2016
Accepted : 24/05/2017
In Press: 28/08/2017
Published: 05/02/2018
Abstract
OBJECTIVES:
The aim of this study was to investigate the relationship between serum infliximab (IFX) levels and changes of RF and ACPA levels in patients with rheumatoid arthritis (RA).
METHODS:
Enzyme-linked immunosorbent assays (ELISA) [Promonitor® IFX R1 (version 2) (Progenika Biopharma, Spain)] were used to measure drug levels and antidrug-antibodies (ADAb) in IFX RA-treated patients (n=19). Disease activity was assessed using DAS28. IgM rheumatoid factor (RF) and IgM, IgA and IgG anti-cyclic citrullinated peptide (ACPA) were determined through ELISA.
RESULTS:
A significant decrease in RF (p=0.01), ACPA IgG (p=0.007), IgM (p=0.01) and IgA (p=0.03) was observed in patients presenting adequate levels of serum IFX. No significant changes to RF or ACPA were observed in patients with undetectable IFX.
CONCLUSIONS:
Data from this study support the hypothesis that the anti-TNF antagonist IFX downregulates autoantibody levels in RA patients when IFX levels are detectable. Larger-scale studies need to be performed to establish RF and ACPA presence as therapeutic response predictive factors.